<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="produced an immediate urgency to discover promising targets for the" exact="treatment" post="of COVID-19. Drug repositioning is an attractive approach that"/>
 <result pre="including promising approved drugs and ongoing clinical trials for prospective" exact="treatment" post="options. In addition, we describe computational approaches to be"/>
 <result pre="era. In December 2019, rumors began to spread about the" exact="prevalence" post="of a new unknown pneumonia-like illness in Wuhan, the"/>
 <result pre="(Zhou etÂ al., 2020a) are various and uncertain. Large-scale serologic" exact="screening" post="provides a better picture of statistics related to asymptomatic"/>
 <result pre="of COVID-19 consists of two evolution types. Type L (70%" exact="prevalence" post="in Wuhan), which is derived from the ancestral type"/>
 <result pre="Wuhan), which is derived from the ancestral type S (30%" exact="prevalence" post="in Wuhan), is more aggressive and contagious (Tang etÂ"/>
 <result pre="is a promising approach to make available an effective, safety-assured" exact="treatment" post="in a timely manner. In this review, we summarize"/>
 <result pre="In this review, we summarize diagnostic approaches, risk groups, available" exact="treatment" post="options, and drug repositioning studies related to COVID-19. Diagnostic"/>
 <result pre="COVID-19. Diagnostic Approaches and Medical Comorbidities Before efficient treatment, precise" exact="diagnosis" post="and classification of patients based on disease severity and"/>
 <result pre="that are associated with worse cases come first. Second, laboratory" exact="detection" post="as a complementary test is done to confirm the"/>
 <result pre="due to the unknown nature of this emergent virus, all" exact="diagnosis" post="was based purely on clinical and radiographic findings (i.e.,"/>
 <result pre="(Huang etÂ al., 2020; Zhu et al., 2020). Now, laboratory" exact="detection" post="includes next-generation sequencing platforms, reverse-transcription polymerase chain reaction (RT-PCR),"/>
 <result pre="al., 2020). Now, laboratory detection includes next-generation sequencing platforms, reverse-transcription" exact="polymerase chain reaction" post="(RT-PCR), and serological methods like enzyme-linked immunoassay. Generally, a"/>
 <result pre="Generally, a patient should be taken into account for laboratory" exact="detection" post="if his or her clinical manifestations and/or radiographical records"/>
 <result pre="2020a). Another procedure that is being used to confirm the" exact="infection" post="is monitoring laboratory features that are associated with worse"/>
 <result pre="comorbidity is due to the pathology of disorder or the" exact="treatment" post="used to cure it such as ACE inhibitors and"/>
 <result pre="ACE2 in the heart, brain, and even in urine after" exact="treatment" post="with ARBs; however, there is limited evidence showing changes"/>
 <result pre="trials sponsored by the WHO named Solidarity will compare different" exact="treatment" post="options, namely, remdesivir, lopinavir/ritonavir dual treatment, lopinavir/ritonavir dual treatment"/>
 <result pre="different treatment options, namely, remdesivir, lopinavir/ritonavir dual treatment, lopinavir/ritonavir dual" exact="treatment" post="with interferon beta 1-alpha, and chloroquine or hydroxychloroquine (paused"/>
 <result pre="injury, ARDS, and death (Zhang etÂ al., 2020c). Accordingly, the" exact="treatment" post="strategy depends on the stage of the disease or"/>
 <result pre="(Stebbing etÂ al., 2020). As examples of the most common" exact="treatment" post="options, chloroquine and hydroxychloroquine, both antimalarial agents with anti-inflammatory"/>
 <result pre="approved for rheumatoid but was later considered as a complementary" exact="treatment" post="in cytokine-release syndrome disease (Kotch etÂ al., 2019). Tocilizumab"/>
 <result pre="the interaction of SARS-CoV-2 and ACE2 is proposed as a" exact="treatment" post="for patients with COVID-19; however, it is not clear"/>
 <result pre="extracellular chromosomal DNA from neutrophil extracellular traps. Accordingly, using this" exact="treatment" post="for patients with ARDS in severe COVID-19 may lead"/>
 <result pre="At present, over 40 antiviral agents are accessible for the" exact="treatment" post="of viral infections. Unfortunately, the most commonly used antiviral"/>
 <result pre="a well-known antihelminthic drug, proved its repurposing potential for the" exact="treatment" post="of Zika infections (Xu etÂ al., 2016). Another interesting"/>
 <result pre="terms of their ability of the possible use for the" exact="treatment" post="of COVID-19, as well as other diseases such as"/>
 <result pre="design that is not prone to off-target effects. Furthermore, virtual" exact="screening" post="of main protease offers emergence of a powerful strategy"/>
 <result pre="repositioning framework, which applies both structure-based drug design and high-throughput" exact="screening" post="approaches to inform putative drug candidates against the main"/>
 <result pre="drug candidates against the main protease of SARS-CoV-2. In silico" exact="screening" post="followed by cell-based validation indicated that ebselen, a drug"/>
 <result pre="tendency of mutational resistance, might show effectiveness in developing robust" exact="treatment" post="options for viral infections (Kaufmann etÂ al., 2018). However,"/>
 <result pre="However, lack of data of the pathophysiology of the SARS-CoV-2" exact="infection" post="restrains the development of small molecule candidates based on"/>
 <result pre="one of them was cause of global concern, a common" exact="treatment" post="may prevent coronavirus to become another lethal annual re-occurrent"/>
 <result pre="reinfection in rhesus macaques infected with SARS-CoV-2BioRxiv202010.1101/2020.03.13.990226 BeigelJ.H.TomashekK.M.DoddL.E.MehtaA.K.ZingmanB.S.KalilA.C.HohmannE.ChuH.Y.LuetkemeyerA.KlineS.Remdesivir for the" exact="treatment" post="of Covid-19 â€&quot; preliminary reportN.Â Engl. J. Med.202010.1056/NEJMoa2007764 BoldescuV.BehnamM.A.M.VasilakisN.KleinC.D.Broad-spectrum"/>
 <result pre="flaviviral infections: dengue, Zika and beyondNat. Rev. Drug Discov.16201756558628473729 BostP.GiladiA.LiuY.BendjelalY.XuG.DavidE.Blecher-GonenR.CohenM.MedagliaC.LiH.Host-viral" exact="infection" post="maps reveal signatures of severe COVID-19 patientsCell202010.1016/j.cell.2020.05.006 BrownA.S.PatelC.J.A review"/>
 <result pre="review on the efficacy and safety of chloroquine for the" exact="treatment" post="of COVID-19J.Â Crit. Care57202027928332173110 De ClercqE.LiG.Approved antiviral drugs over"/>
 <result pre="targets and beyondBr. J. Pharmacol.1522007213717549046 GautretP.LagierJ.-C.ParolaP.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trialInt."/>
 <result pre="proteases using luciferase-based biosensorsJ.Â Virol.872013119551196223986593 KitchenD.B.DecornezH.FurrJ.R.BajorathJ.Docking and scoring in virtual" exact="screening" post="for drug discovery: methods and applicationsNat. Rev. Drug Discov.3200493594915520816"/>
 <result pre="discovery: methods and applicationsNat. Rev. Drug Discov.3200493594915520816 KotchC.BarrettD.TeacheyD.T.Tocilizumab for the" exact="treatment" post="of chimeric antigen receptor TÂ cell-induced cytokine release syndromeExpert"/>
 <result pre="side of Yersinia pestisTrends Microbiol.24201619019726698952 PizzornoA.PadeyB.TerrierO.Rosa-CalatravaM.Drug repurposing approaches for the" exact="treatment" post="of influenza viral infection: reviving old drugs to fight"/>
 <result pre="replicationProc. Natl. Acad. Sci. U S A1052008161191612418852458 RotheC.SchunkM.SothmannP.BretzelG.FroeschlG.WallrauchC.ZimmerT.ThielV.JankeC.GuggemosW.Transmission of 2019-nCoV" exact="infection" post="from an asymptomatic contact in GermanyNew Engl. J. Med.382202097097132003551"/>
 <result pre="novel coronavirus Infection: proposal of conventional serologic assays for disease" exact="diagnosis" post="and infection monitoring [Commentary/Review]J.Â Med. Virol.92202046446732031264 XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.Identification of small-molecule"/>
 <result pre="Infection: proposal of conventional serologic assays for disease diagnosis and" exact="infection" post="monitoring [Commentary/Review]J.Â Med. Virol.92202046446732031264 XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.Identification of small-molecule inhibitors of"/>
 <result pre="[Commentary/Review]J.Â Med. Virol.92202046446732031264 XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.Identification of small-molecule inhibitors of Zika virus" exact="infection" post="and induced neural cell death via a drug repurposing"/>
 <result pre="binding and antiviral drug designJ.Â Virol.8220082515252718094151 YuP.ZhuJ.ZhangZ.HanY.HuangL.A familial cluster of" exact="infection" post="associated with the 2019 novel coronavirus indicating potential person-to-person"/>
 <result pre="improved Î±-ketoamide inhibitorsScience368202040941232198291 ZhangW.ZhaoY.ZhangF.WangQ.LiT.LiuZ.WangJ.QinY.ZhangX.YanX.The use of anti-inflammatoryÂ drugs in the" exact="treatment" post="of people with severe coronavirus disease 2019 (COVID-19): the"/>
</results>
